Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Return on Capital Employed (2020 - 2023)

Historic Return on Capital Employed for ADC Therapeutics (ADCT) over the last 4 years, with Q3 2023 value amounting to 26.57%.

  • ADC Therapeutics' Return on Capital Employed fell 263100.0% to 26.57% in Q3 2023 from the same period last year, while for Sep 2023 it was 26.57%, marking a year-over-year decrease of 263100.0%. This contributed to the annual value of 0.0% for FY2022, which is N/A changed from last year.
  • Per ADC Therapeutics' latest filing, its Return on Capital Employed stood at 26.57% for Q3 2023, which was down 263100.0% from 26.62% recorded in Q2 2023.
  • In the past 5 years, ADC Therapeutics' Return on Capital Employed ranged from a high of 0.26% in Q3 2022 and a low of 108.37% during Q3 2020
  • For the 4-year period, ADC Therapeutics' Return on Capital Employed averaged around 18.08%, with its median value being 0.53% (2021).
  • As far as peak fluctuations go, ADC Therapeutics' Return on Capital Employed surged by 1079600bps in 2021, and later crashed by -269200bps in 2023.
  • ADC Therapeutics' Return on Capital Employed (Quarter) stood at 108.37% in 2020, then skyrocketed by 100bps to 0.38% in 2021, then plummeted by -6621bps to 25.27% in 2022, then fell by -5bps to 26.57% in 2023.
  • Its last three reported values are 26.57% in Q3 2023, 26.62% for Q2 2023, and 27.28% during Q1 2023.